Sanofi SA (SNY) on Tuesday said that the European Commission has given the green light to Wayrilz or rilzabrutinib for treating immune thrombocytopenia in adults who haven't had success with other treatments.
This follows a positive recommendation from the European Medicines Agency's CHMP. Wayrilz is a new oral, reversible BTK inhibitor that aims to tackle the immune system issues causing ITP through a multi-immune modulation approach.
The decision is backed by findings from the phase 3 LUNA 3 study, which revealed notable improvements in durable platelet response, quicker response times, and enhanced quality of life compared to a placebo. Wayrilz is already approved in both the United States and the UAE.
SNY is currently trading at $48.49, up $0.46 or 0.95 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.